In the rapidly evolving landscape of therapeutic nucleic acid development, the ability to visualize and quantify gene delivery efficiency is paramount. CD BioGlyco provides a premier reporter gene mRNA synthesis service, designed to empower researchers with high-purity, ready-to-transfect messenger RNA (mRNA) molecules. Reporter genes serve as indispensable tools in biotechnology, acting as surrogate markers that reflect the successful uptake and translation of nucleic acid cargo within target cells. Our service bridges the gap between complex molecular design and functional biological validation. By synthesizing mRNA encoding well-characterized proteins such as firefly luciferase, enhanced green fluorescent protein, and beta-galactosidase (β-Gal), we enable real-time monitoring of gene expression kinetics and spatial distribution. Whether you are optimizing a lipid nanoparticle (LNP) formulation or evaluating a novel tissue-specific promoter, our reporter gene mRNA solutions provide the clarity and precision required for data-driven decisions.
Advanced In Vitro Transcription (IVT)
We utilize high-fidelity T7 RNA polymerase systems optimized for high-yield production. Our IVT service is engineered to minimize the generation of double-stranded RNA (dsRNA) by-products, which are known to trigger innate immune responses via toll-like receptors (TLRs).
Precision Co-Transcriptional Capping
To ensure maximum translation efficiency and transcript stability, we employ advanced capping technologies, including the anti-reverse cap analog. These technologies yield a cap-1 structure that mimics natural eukaryotic mRNA, significantly enhancing in vivo performance.
Custom Nucleotide Modification
We offer comprehensive chemical modification options, such as the incorporation of N1-methylpseudouridine or 5-methoxyuridine. These modifications are strategically used to reduce immunogenicity and increase the half-life of the reporter protein expression.
As a critical component of our therapeutic nucleic acid development platform, the reporter gene mRNA synthesis service at CD BioGlyco is tailored to meet the rigorous demands of both academic research and industrial drug discovery. Our scope encompasses the production of a wide array of reporter constructs:
The process begins with the optimization of the DNA template. We design the 5' and 3' untranslated regions (UTRs) to maximize translation efficiency and include a poly-A tail of optimal length (typically 100-120 nucleotides) to prevent exonuclease degradation.
The circular DNA template is linearized using high-specificity restriction enzymes. We perform rigorous QC using agarose gel electrophoresis and sequence verification to ensure the template is "clean" and accurate.
The linearized DNA undergoes IVT in a controlled environment. During this stage, we incorporate modified nucleotides and capping analogs according to the client's specific requirements to achieve the desired biological profile.
Following synthesis, the DNA template is removed using DNase I. We then employ advanced purification techniques, such as lithium chloride precipitation or spin-column chromatography, to remove residual enzymes, free nucleotides, and short abortive transcripts.
For applications requiring ultra-low immunogenicity, we offer high-performance liquid chromatography (HPLC) or fast protein liquid chromatography (FPLC) purification. This step is crucial for removing dsrna contaminants that interfere with experimental results.
Every batch of reporter gene mRNA undergoes a final battery of tests, including fragment analyzer or bioanalyzer assessment for integrity, nanodrop for concentration, and endotoxin testing to ensure compatibility with sensitive cell types and in vivo models.
DoI: 10.3390/cells12222596
Journal: Cells
IF: 5.2
Published: 2023
Results: This article presents a reporter gene-based quantitative real-time PCR (qRT-PCR) assay to detect Rho-dependent termination (RDT) and Rho-independent termination (RIT) in vivo. Due to biases in reverse transcription and PCR amplification, direct measurement of RDT sites is challenging. The researchers used a 77 bp argX gene (coding tRNAarg) from Brevibacterium albidum as the reporter, fusing it with gal operon sequences containing or lacking RDT/RIT regions to construct plasmids. By quantifying tRNAarg levels via qRT-PCR (with consistent tRNAarg degradation rates ensuring reliability), they determined RDT efficiencies at galET (36%), galTK (26%), and galM end (63%), and RIT efficiency at gal operon end (33%). This method avoids translation bias and exogenous substrates, offering a reliable, quantitative tool for studying bacterial transcription termination.
Fig.1 Plasmids used to measure RDT efficiency in vivo and their construction strategy. (N, et al., 2023)
Drug Delivery System (DDS) Evaluation
Testing the efficiency of LNPs, polymers, or viral vectors in delivering nucleic acid cargo to specific organs.
Vaccine Development
Assessing the translation efficiency of mrna vaccine platforms in various tissue environments.
Cell Therapy Research
Monitoring the persistence and expression levels of transcripts in chimeric antigen receptor (CAR) T-cells or stem cells.
Gene Regulation Studies
Investigating the impact of different UTR sequences or chemical modifications on protein production kinetics.
Exceptional Purity
Our specialized purification protocols eliminate dsRNA and other impurities, ensuring a high signal-to-noise ratio in your assays.
Flexible Scalability
We provide synthesis services ranging from microgram quantities for pilot studies to gram-scale production for extensive in vivo trials.
Expert Technical Support
Our team of Ph.D. level scientists provides end-to-end consultation, from sequence optimization to troubleshooting your transfection experiments.
Integrated Platform
As part of a larger glycobiology and nucleic acid ecosystem, we offer seamless transitions to downstream analysis and modification services.
"The EGFP mRNA provided by CD BioGlyco showed significantly higher expression and lower toxicity in our primary neuronal cultures compared to other vendors. The HPLC purification made a noticeable difference in our in vivo studies."
– C.D., Senior Researcher
"Working with CD BioGlyco's team was seamless. Their technical advice on using N1-methylpseudouridine modifications helped us achieve a 5-fold increase in luciferase signal in our DDS evaluation."
– A.G., Project Leader
"We rely on CD BioGlyco for our large-scale reporter mRNA needs. The consistency between batches is excellent, which is critical for our high-throughput screening assays."
- E.V., Director of Discovery
CD BioGlyco is committed to providing the scientific community with the highest quality reporter gene mRNA synthesis service. By combining our expertise in therapeutic oligonucleotide synthesis with cutting-edge technology, we ensure your research is supported by reliable and high-performance tools. Please feel free to contact us for more information about our services or to request a customized quote.
Reference
